Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression.

By P. Mease, A. Kivitz, F. Burch, E. Siegel, S. Cohen, P. Ory, D. Salonen, J. Rubenstein, J. Sharp, W. Tsuji. Arthritis & Rheumatism, 2004

918 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial (2005, background): “Some of the current treatments for PsA, including sulfasalazine (19), leflunomide (33), and etanercept (8, 9) have been well assessed; many of the other commonly used therapies have been adapted from treatment of RA and their use in PsA is not supported by clinical trial data.”
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment (2009, background): “Therapeutic trials of highly effective biological therapies such as tumour necrosis factor (TNF) blockers in PsA have shown a reduction in disease activity and a corresponding reduction in radiological progression.”